Eybna Technologies

growth-positive

The article discusses the pioneering work of Eybna Technologies in the field of cannabis science. Eybna has made significant discoveries in the study of terpenes, cannabinoids, and their interactions with the endocannabinoid system. In 2020, Eybna discovered a cannabinoid formulation that effectively blocked the novel coronavirus from penetrating living cells. They are now conducting clinical studies on the formulation as a potential treatment for COVID-19. Eybna has also developed receptor-specific cannabinoid formulations, which are unique in the industry. These formulations target specific wellness goals and are composed of ingredients that are effective for producing certain effects, such as pain relief or sleep. Eybna plans to introduce these formulations globally and partner with other companies in the cannabis and CBD industry. The article emphasizes the potential of the cannabis industry to bring about change and innovation in the pharmaceutical industry and improve the quality of life on a global scale.

growth-positive

Eybna has been selected as an R&D partner by Gat Foods (IBBL) to create functional beverages using terpene formulations. The partnership marks a major milestone in the international functional beverage industry. The Global Functional Beverage Market is projected to be worth USD 198 billion by 2026. Eybnas new Receptor Specific™ Line, which offers botanical formulations for various wellness needs, was launched in October 2021. The R&D partnership between Eybna and Gat Foods (IBBL) will begin with a commercial pilot in Israel and expand to other countries. Eybna is a technology company specializing in botanical medicine, while Gat Foods (IBBL) is one of the largest beverage manufacturers and distributors in Israel.

growth-positive

Eybna, a technology company specializing in cannabis and botanical medicine, has launched its Functional Line. The line includes data-driven phytochemical formulations designed to meet wellness needs such as focus, sleep, anxiety, pain, inflammation, and mood management. The formulations are the result of nearly a decade of scientific research and biological data analysis. The launch includes 10 Receptor-Specific terpene and cannabinoid proprietary formulations. Eybnas CEO and Co-founder, Nadav Eyal, stated that the new line of formulations is an important milestone in Eybnas efforts towards predictable cannabis consumption.

growth-positive

Israeli company Eybna specializes in terpene formulations for the cannabis industry. Terpenes are organic compounds that give scents, tastes, and health benefits to fruits, flowers, and plants, including cannabis. Eybnas proprietary terpene-based formulations are used by manufacturers in the cannabis space to enhance their products. The companys research focuses on the therapeutic properties of terpenes and other cannabis phytochemicals. Eybna offers customized terpene formulations for specific sensations or medical needs. They are also collaborating with CannaSoul Analytics to investigate terpenes as an antiviral treatment for COVID-19. Eybnas growth is positive, as more companies are interested in incorporating terpenes into their products.